Lilly Asia Ventures has successfully closed its US$10million strategic investment to Tianjin CanSino Biotechnology, a company engaged in research, development, and commercialization of vaccines.

Founding in 2008, Lilly Asia Ventures focuses on equity investments in the life sciences and healthcare sectors in Asia, particularly in China. It is affiliated with Eli Lilly and Company, a fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world with 135 years of history.

Global Law Office acted as the PRC legal counsel of Lilly Asia Ventures in the transaction.  The team was led by our Shanghai-based partner, Ms. Jane YING, as well as Ms. Amy DAI was also a key member of the team.